Vitrolife

Vitrolife AB is Sweden's under-the-radar IVF market leader and probably the most misunderstood healthcare stock on OMX Stockholm in 2026. Q1 2026 earnings (reported April 23) showed the strength below the surface: gross margin 59.9% (up from 57.4%), cash flow +149% to SEK 172M, net debt/EBITDA improved to 0.6×. But reported revenue fell 4% to SEK 807M — and that dominated perception. What the headline obscures: it's an FX effect; organically Vitrolife grew 5% in local currencies.

Vitrolife operates in three product segments: Consumables (embryo culture media, pipettes, micro-needles — grew +15% in Q1), Technologies (EmbryoScope time-lapse imaging — +5%), and Genetics (preimplantation genetic testing via the Igenomix subsidiary acquired in 2021 for $1.5B — Q1 -6% due to timing of genomic kit orders from major clinic chains).

The strategic direction from CEO Bronwyn Brophy O'Connor (since June 2024) has three pillars: (1) Growth with improved clinic segmentation and combined EmbryoScope + lab control solutions; (2) Innovation with AI-driven embryo selection to improve IVF clinic workflow efficiency; (3) Operational Excellence with IT digitization and cost optimization. AI embryo selection is the key 2026/27 differentiator versus Hamilton Thorne and Cooper Surgical.

Vitrolife is an OMX Stockholm stock and not in the classic US 13F universe. The institutional anchor structure is Nordic-specialist: Vidar AB (a Swedish family office) holds ~5%, Lannebo Småbolag ~4%, SEB Stiftelser ~3.5%, Capital Group Companies ~3%, plus BlackRock and Vanguard with ~2% each via healthcare ETF vehicles.

The most important smart-money data point: Investment AB Bure — a Swedish industrial holding company — has systematically bought Vitrolife shares in 2025 and now sits at ~12% stake. Bure successfully bought Mycronic in 2020-2022 before it became a 10-year compound. This is the smart-money anchor in the Swedish mid-cap healthcare scene.

Insider activity: new CEO Bronwyn Brophy O'Connor (ex-J&J Vision, ex-Sanofi China head) hasn't sold a single share since taking the position — has built stock comp instead. Consistent with her public statements on the 3-pillar strategy. CFO Anna Ahlberg has been in the role since 2017 and even bought shares at the 2024 lows — an additional quality signal.

Vitrolife trades at a forward P/E of 21.62× (historically low — 5-year median 35×), EV/EBITDA of 15.94× (median 22×), and PEG of 2.02. EV/sales of ~4× is cheap for the healthcare-devices sector. Sum-of-parts: Consumables segment (highest margin ~70%, ~50% revenue) → EBITDA SEK 600-700M/year × 18× = SEK 11-12B. Technologies (EmbryoScope, ~25% revenue) → EBITDA SEK 200M × 15× = SEK 3B. Genetics (Igenomix remainder, ~25% revenue, lowest margin) → EBITDA SEK 100M × 8× = SEK 0.8B. Sum: SEK 14.8-15.8B — almost exactly today's market cap of SEK 14.1B. Analyst consensus (5 analysts): target SEK 172.20 (+65%), range SEK 131-215, median 'strong_buy'. Bull case (AI embryo selection launch + Americas +15% growth + Genetics recovery): SEK 200-220. Bear case (further Igenomix impairment + China IVF restrictions): SEK 70-80.

1. July 2026: Q2 2026 earnings — critical test whether Genetics segment is growing again (Q1 was -6% on timing); also first AI embryo selection pilot results expected
2. Q3/Q4 2026: AI embryo selection full roll-out + capital markets day — if the AI workflow solution shows SEK 200M+ 2027 revenue contribution, that's a clear re-rating catalyst
3. Q1 2027: China IVF regulatory clarity + Igenomix profit stabilization — either the bear case materializes or Genetics segment turns back to growth

Vitrolife is, for me, a 'broken IPO recovery' story in 2026 with real compound optionality. Gross margin at 59.9% and +15% consumables growth show the core is intact — only the Igenomix acquisition still echoes. If new CEO O'Connor steers Genetics back to growth in 2026/27, a re-rating to SEK 170 is likely. Position size for me: 1-2% because of high beta and FX sensitivity. My add-trigger: stock below SEK 95 (additional 9% discount). My sell: SEK 175+ or another Igenomix impairment. Bure as a 12% anchor gives me confidence. The IVF market grows globally 6-8% annually, demographic megatrend in full force — Vitrolife is the purest play on it in Europe.